stockrowTwist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
Follow TWST
Alert me
Twist Bioscience Corporation (TWST) EV/Sales
As of 30 October 2026, Twist Bioscience Corporation (TWST) trades at a EV/Sales of 21.7×. Over the past ten years it has ranged from −1.1× (November 2018) to 88.9× (January 2021); the current reading is higher than 80% of that period. That is above the Biotechnology industry median of 9.9× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.9× | (49.73%) |
| FY2024 | 7.7× | 127.55% |
| FY2023 | 3.4× | (53.05%) |
| FY2022 | 7.3× | (79.74%) |
| FY2021 | 35.8× | 19.84% |
| FY2020 | 29.9× | 209.26% |
| FY2019 | 9.7× | — |
| FY2018 | −1.1× | — |
| FY2017 | −1.1× | — |
| FY2016 | −1.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 14.5× | 114.11% |
| Mar 2026 | 6.8× | 51.22% |
| Dec 2025 | 4.5× | 15.11% |
| Sep 2025 | 3.9× | (28.46%) |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PCVX Vaxcyte, Inc. compare | n/m |
| JAZZ Jazz Pharmaceuticals PLC compare | 3.4× |
| BMRN BioMarin Pharmaceutical Inc. compare | 4.3× |
| TECH Bio-Techne Corp compare | 9.3× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 9.4× |
| CAI Caris Life Sciences,�Inc. compare | 9.4× |
| TWST Twist Bioscience Corporation | 21.7× |
| KYMR Kymera Therapeutics, Inc. compare | 112× |
| SMMT Summit Therapeutics PLC compare | 16,856× |
| Biotechnology industry median | 9.9× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)